A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
Edward Wolin, Alain Mita, Amit Mahipal, Tim Meyer, Johanna Bendell, John Nemunaitis, Pam N. Munster, Luis Paz-Ares, Ellen H. Filvaroff, Shaoyi Li, Kristen Hege, Hans de Haan, Monica Mita
Dive into the research topics of 'A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms'. Together they form a unique fingerprint.